A malaria shot for babies shows real protection in Kenya
Malaria is one of the biggest threats to young children in Africa. Now, a single injection appears to cut the risk of infection for many months. In a new trial in western Kenya, a long-acting antibody called L9LS reduced malaria cases by 43% in children under five.
That matters because current prevention tools, like bed nets and preventive medicines, don’t work perfectly for every child. Families in high-transmission areas often face repeated infections that can lead to fever, anemia, and hospital stays.
Malaria is caused by a parasite spread by mosquitoes. In parts of western Kenya, transmission happens year-round, not just in a single rainy season. Young children are especially vulnerable because their immune systems are still developing.
The study focused on children aged 5 to 59 months in Siaya County, Kenya, where malaria is common. Researchers tested a monoclonal antibody called L9LS, which is designed to block the parasite before it can cause illness. Unlike daily pills, this shot is meant to last for months.
Old prevention vs. a new approach
For years, families have relied on bed nets, indoor spraying, and preventive medicines given seasonally. These tools help, but gaps remain. Some children miss doses, mosquitoes develop resistance, and bed nets wear out.
But here’s the twist: L9LS is not a vaccine. It’s a ready-made antibody that gives immediate protection. Think of it like a guard posted at the door, stopping the parasite before it gets inside. The goal is a single shot that lasts through the malaria season.
Antibodies are proteins the body makes to fight invaders. L9LS is a lab-made antibody that targets a key part of the malaria parasite. When given by injection, it circulates in the blood and blocks the parasite from infecting liver cells.
A simple analogy: imagine the parasite as a key trying to unlock a door. L9LS fits the lock so the key can’t turn. The antibody stays active for months, offering protection without daily pills.
The study design in plain terms
Researchers in Kenya ran a two-part, double-blind trial. First, they tested safety and different doses in small groups of children aged 5 months to 10 years. Then, in the main efficacy part, they enrolled 324 children aged 5 to 59 months.
Children were randomly assigned to one of three groups: two doses of L9LS (at baseline and at 6 months), one dose at baseline with a placebo at 6 months, or placebo at both times. All children were followed for 12 months with monthly clinic visits and blood tests. The main goal was to see how many children developed malaria during that period.
In the two-dose group, 70 of 106 children (66%) had at least one malaria infection over 12 months. In the placebo group, 91 of 110 children (83%) were infected. That translates to a protective efficacy of 42.7%—meaning the antibody cut the risk of infection by nearly half.
Safety was closely monitored. Across all study parts, only four serious adverse events occurred after L9LS injections and two after placebo, none of which were linked to the antibody. Most side effects were mild and resolved quickly.
But there's a catch. The protection was lower than what was seen in earlier seasonal trials. The authors suggest that higher doses may be needed in areas with year-round transmission.
What experts are saying
The trial was funded by the Gates Foundation and published in The Lancet. The authors conclude that L9LS is safe and shows meaningful protection in young children, but they note that dose optimization may be key for high-transmission settings.
What this means for families
This shot is not yet available for routine use. If you’re a parent or caregiver in a malaria-endemic area, talk to your local health provider about current prevention options, such as bed nets and seasonal preventive medicines. Clinical trials like this one help scientists figure out the best way to protect children in the years ahead.
Limitations to keep in mind
This was a phase 2 trial in one region of Kenya. The sample size was moderate, and the follow-up lasted 12 months. Results in other settings may differ, especially where malaria transmission is seasonal or where different parasite strains circulate.
What happens next
Researchers are now exploring whether a higher dose of L9LS can boost protection in young children. Larger trials in multiple countries will help confirm safety and effectiveness. If results hold up, regulators could consider approval in the coming years, but no timeline is set yet.
